Home Cart Sign in  
Chemical Structure| 7343-34-2 Chemical Structure| 7343-34-2

Structure of 7343-34-2

Chemical Structure| 7343-34-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 7343-34-2 ]

CAS No. :7343-34-2
Formula : C4H7N3
M.W : 97.12
SMILES Code : CC1=NN=C(C)N1
MDL No. :MFCD00656686
InChI Key :XYYXDARQOHWBPO-UHFFFAOYSA-N
Pubchem ID :139001

Safety of [ 7343-34-2 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Computational Chemistry of [ 7343-34-2 ] Show Less

Physicochemical Properties

Num. heavy atoms 7
Num. arom. heavy atoms 5
Fraction Csp3 0.5
Num. rotatable bonds 0
Num. H-bond acceptors 2.0
Num. H-bond donors 1.0
Molar Refractivity 26.31
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

41.57 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.6
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.27
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

0.42
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-0.13
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.46
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.52

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.14
Solubility 7.02 mg/ml ; 0.0723 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-0.7
Solubility 19.2 mg/ml ; 0.198 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.55
Solubility 2.72 mg/ml ; 0.028 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.7 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

2.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.49

Application In Synthesis of [ 7343-34-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 7343-34-2 ]

[ 7343-34-2 ] Synthesis Path-Downstream   1~35

  • 1
  • [ 1117-96-0 ]
  • [ 7343-34-2 ]
  • [ 32675-46-0 ]
  • 2
  • [ 625-77-4 ]
  • [ 563-41-7 ]
  • [ 7343-34-2 ]
  • 3
  • [ 625-77-4 ]
  • [ 7343-34-2 ]
  • 6
  • [ 7343-34-2 ]
  • [ 471-25-0 ]
  • [ 156969-35-6 ]
  • 7
  • [ 62-55-5 ]
  • [ 1068-57-1 ]
  • [ 7343-34-2 ]
  • 8
  • [ 7343-34-2 ]
  • [ 112-29-8 ]
  • [ 159255-04-6 ]
YieldReaction ConditionsOperation in experiment
22% With sodium hydroxide; In N-methyl-acetamide; water; (c) Preparation of 1-decyl-<strong>[7343-34-2]3,5-dimethyl-1,2,4-triazole</strong> A mixture of <strong>[7343-34-2]3,5-dimethyl-1,2,4-triazole</strong> (6.0 parts; 0.062 mol ex (b) above) and 1-bromodecane (14.4 parts; 0.065 mol) in dimethylformamide (16 ml) was heated together at 120° C. for 23 hours. The cooled reaction mixture was diluted with water (100 ml), a solution of sodium hydroxide (2.62 parts; 0.065 mol) in water (100 ml) added, and the product extracted into ether (3*50 ml). After drying over magnesium sulphate the solution was evaporated to yield a pale yellow oil (3.3 parts; 22percent theory). Infra red analysis: vmax (film): 2923, 2853, 1515, 1341, 701cm-1. Proton NMR: delta(CDCl3; 0.9(t,3H); 1.2-1.4(m,14H); 1.7-1.9(m,2H); 2.3(s,3H); 2.4(s,3H); 4.0(t,2H)ppm. Mass spec: m/z(Br): 238(M+H+, 100percent).
  • 9
  • [ 7343-34-2 ]
  • 2Cu(1+)*(C4H2S(CHNCH2)(CHNCH2C(CH3)2))2*2CH3CN*2ClO4(1-) = [Cu2(C4H2S(CHNCH2)(CHNCH2C(CH3)2))2(CH3CN)2][ClO4]2 [ No CAS ]
  • silver perchlorate [ No CAS ]
  • Cu4Ag((C4H2S(CHNCH2)(CHNCH2C(CH3)2))2)2(C4N3H6)2(3+)*3ClO4(1-) = [Cu4Ag((C4H2S(CHNCH2)2(C(CH3)2))2)2(C4N3H6)2][ClO4]3 [ No CAS ]
  • 10
  • [ 7343-34-2 ]
  • Cu2(C4H2O(CHNCH2)(CHNCH2C(CH3)2))2(CH3CN)2(2+)*2ClO4(1-) = [Cu2(C4H2O(CHNCH2)(CHNCH2C(CH3)2))2(CH3CN)2][ClO4]2 [ No CAS ]
  • silver perchlorate [ No CAS ]
  • Cu4Ag((C4H2O(CHNCH2)(CHNCH2C(CH3)2))2)2(C4N3H6)2(3+)*3ClO4(1-) = [Cu4Ag((C4H2O(CHNCH2)2(C(CH3)2))2)2(C4N3H6)2][ClO4]3 [ No CAS ]
  • 11
  • [ 7343-34-2 ]
  • Cu2(C4H2O(CHNCH2)(CHNCH2C(CH3)2))2(CH3CN)2(2+)*2ClO4(1-) = [Cu2(C4H2O(CHNCH2)(CHNCH2C(CH3)2))2(CH3CN)2][ClO4]2 [ No CAS ]
  • [ 14057-91-1 ]
  • Cu5((C4H2O(CHNCH2)(CHNCH2C(CH3)2))2)2(C4N3H6)2(3+)*3ClO4(1-) = [Cu5((C4H2O(CHNCH2)(CHNCH2C(CH3)2))2)2(C4N3H6)2][ClO4]3 [ No CAS ]
  • 12
  • [ 7343-34-2 ]
  • 2Cu(1+)*(C4H2S(CHNCH2)(CHNCH2C(CH3)2))2*2CH3CN*2ClO4(1-) = [Cu2(C4H2S(CHNCH2)(CHNCH2C(CH3)2))2(CH3CN)2][ClO4]2 [ No CAS ]
  • [ 14057-91-1 ]
  • Cu5((C4H2S(CHNCH2)(CHNCH2C(CH3)2))2)2(C4N3H6)2(3+)*3ClO4(1-) = [Cu5((C4H2S(CHNCH2)(CHNCH2C(CH3)2))2)2(C4N3H6)2][ClO4]3 [ No CAS ]
  • 13
  • [ 7343-34-2 ]
  • [ 14057-91-1 ]
  • [Cu2(C4H2O(CHNCH2)(CHNCH2CH2))2(CH3CN)2](2+)*2ClO4(1-) = [Cu2(C4H2O(CHNCH2)(CHNCH2CH2))2(CH3CN)2](ClO4)2 [ No CAS ]
  • Cu5((C4H2O(CHNCH2)(CHNCH2CH2))2)2(C2N3(CH3)2)2(3+)*3ClO4(1-) = [Cu5((C4H2O(CHNCH2)(CHNCH2CH2))2)2(C4N3H6)2][ClO4]3 [ No CAS ]
  • 14
  • [ 7343-34-2 ]
  • [ 865-38-3 ]
  • [ 89210-86-6 ]
  • 15
  • ammonium thiocyanate [ No CAS ]
  • [ 7343-34-2 ]
  • cobalt(II) nitrate [ No CAS ]
  • [ 89210-77-5 ]
  • 16
  • ammonium thiocyanate [ No CAS ]
  • [ 7343-34-2 ]
  • nickel(II) nitrate [ No CAS ]
  • [ 89210-78-6 ]
  • 17
  • ammonium thiocyanate [ No CAS ]
  • [ 7343-34-2 ]
  • manganese(II) nitrate [ No CAS ]
  • [ 89231-70-9 ]
  • 18
  • [ 7343-34-2 ]
  • potassium borohydride [ No CAS ]
  • potassium hydrotris(3,5-dimethyl-1,2,4-triazol-1-yl)borate [ No CAS ]
  • 19
  • [ 7343-34-2 ]
  • [ 557-42-6 ]
  • [ 89210-83-3 ]
  • 20
  • [ 7343-34-2 ]
  • potassium borohydride [ No CAS ]
  • potassium bis[hydrotris[3,5-dimethyl(1,2,4-triazolyl)]borato] [ No CAS ]
  • 21
  • [ 7343-34-2 ]
  • [ 64-18-6 ]
  • zinc(II) oxide [ No CAS ]
  • [ 1146622-14-1 ]
  • 22
  • [ 7343-34-2 ]
  • [ 64-18-6 ]
  • zinc(II) nitrate hexahydrate [ No CAS ]
  • [ 7664-39-3 ]
  • [ 124-40-3 ]
  • [ 1146622-17-4 ]
  • [Zn(3,5-dimethyl-1,2,4-triazolato)(formate)]*0.167Me2NH*0.25H2O [ No CAS ]
  • 23
  • [ 7343-34-2 ]
  • [ 64-18-6 ]
  • zinc(II) nitrate hexahydrate [ No CAS ]
  • [ 7664-39-3 ]
  • [ 124-40-3 ]
  • [ 1146622-17-4 ]
  • [Zn(3,5-dimethyl-1,2,4-triazolato)(formate)]*0.167Me2NH*0.25H2O [ No CAS ]
  • 24
  • [ 7343-34-2 ]
  • zinc(II) nitrate hexahydrate [ No CAS ]
  • [ 7664-39-3 ]
  • [ 141-53-7 ]
  • [ 124-40-3 ]
  • [ 1146622-17-4 ]
  • [Zn(3,5-dimethyl-1,2,4-triazolato)(formate)]*0.167Me2NH*0.25H2O [ No CAS ]
  • 25
  • [ 7343-34-2 ]
  • zinc(II) nitrate hexahydrate [ No CAS ]
  • [ 7664-39-3 ]
  • [ 141-53-7 ]
  • [ 124-40-3 ]
  • [ 1146622-17-4 ]
  • [Zn(3,5-dimethyl-1,2,4-triazolato)(formate)]*0.167Me2NH*0.25H2O [ No CAS ]
  • 26
  • [ 7343-34-2 ]
  • zinc(II) nitrate hexahydrate [ No CAS ]
  • [ 7664-39-3 ]
  • [ 1146622-17-4 ]
  • 27
  • [ 7343-34-2 ]
  • zinc(II) nitrate hexahydrate [ No CAS ]
  • [ 7664-39-3 ]
  • [ 1146622-17-4 ]
  • 28
  • [ 7343-34-2 ]
  • zinc(II) nitrate hexahydrate [ No CAS ]
  • [ 68-12-2 ]
  • [Zn(3,5-dimethyl-1,2,4-triazolato)(formate)]*0.167Me2NH*0.25H2O [ No CAS ]
  • 29
  • [ 7343-34-2 ]
  • [ 930-68-7 ]
  • [ 1240490-03-2 ]
  • 30
  • [ 7343-34-2 ]
  • [ 78-94-4 ]
  • [ 1240490-02-1 ]
  • 31
  • [ 7343-34-2 ]
  • [ 3680-02-2 ]
  • [ 1240490-04-3 ]
  • 32
  • [ 7343-34-2 ]
  • 1,1-dimethylethyl 6-(3,4-dichlorophenyl)-1-([(methylsulfonyl)oxy]methyl)-3-azabicyclo[4.1.0]heptane-3-carboxylate [ No CAS ]
  • 1,1-dimethylethyl (1R,6S/1S,6R)-6-(3,4-dichlorophenyl)-1-[(3,5-dimethyl-1H-1,2,4-triazol-1-yl)methyl]-3-azabicyclo[4.1.0]heptane-3-carboxylate [ No CAS ]
YieldReaction ConditionsOperation in experiment
General procedure: The example reported for derivatives 22/23 find general application for all the other N-linked heterocycles. Sodium hydride 60percent dispersed in mineral oil was added at 0 °C to a solution of 3-(trifluoromethyl)-1H-pyrazole in dry DMF. The mixture was stirred at this temperature for 15 min, then for an additional 5 min at room temperature. A solution of derivative 45 in dry DMF (2 ml) was then added and the mixture was stirred at 50 °C for 3 h 30 min. After cooling to RT, a saturated NH4Cl solution was added and the mixture was extracted with Et2O (2.x.). The organic phase was washed with brine, dried over Na2SO4 and concentrated in vacuo. The residue was purified by Silica gel flash chromatography (gradient ethyl acetate in cyclohexane from 5 to 40percent) to give the intermediate BOC protected compound 22 and the intermediate BOC protected compound 23.
  • 33
  • [ 7343-34-2 ]
  • [ 362610-29-5 ]
  • [ 1318780-36-7 ]
YieldReaction ConditionsOperation in experiment
Step 2: Benzyl 2-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)-3-oxobutanoate To a stirring solution of 3,5-dimethyl-1-H-[1,2,4]-triazole (0.502 g, 5.16 mmol) in THF (36.9 ml) was added NaH (0.199 g, 4.98 mmol). After stirring at RT for 10 mins 2-bromo-3-oxo-butyric acid benzyl ester (step 1) (1.0 g, 3.69 mmol) was added. The mixture was stirred at 40° C. for 30 mins and then allowed to cool to RT. The mixture was absorbed onto silica and purification by chromatography on silica eluting with 0-10percent DCM/MeOH afforded the title compound as an orange oil ; LC-MS Rt 1.95 mins; MS m/z 288.3 [M+H]+; Method LowpH_v001.
  • 34
  • [ 7343-34-2 ]
  • [ 100-21-0 ]
  • [ 557-34-6 ]
  • [ 7732-18-5 ]
  • [ 74-89-5 ]
  • 2Zn(2+)*2C6H4(COO)(COOH)(1-)*2(CH3)2C2N3(1-)*2H2O*CH3NH2=[Zn2(C6H4(COO)COOH)2((CH3)2C2N3)2]*2H2O*CH3NH2 [ No CAS ]
  • 35
  • [ 7343-34-2 ]
  • [ 618-83-7 ]
  • [ 7732-18-5 ]
  • [ 5970-45-6 ]
  • [ 68-12-2 ]
  • ([Zn5(3,5-dimethyl-1H-1,2,4-triazole-H)3(5-hydroxyisophthalic acid-2H)3(OH)]*N,N'-dimethylformamide*5H2O)n [ No CAS ]
 

Historical Records

Categories

Related Parent Nucleus of
[ 7343-34-2 ]

Triazoles

Chemical Structure| 4923-01-7

A158293 [4923-01-7]

5-Methyl-4H-1,2,4-triazol-3-amine

Similarity: 0.76

Chemical Structure| 59660-30-9

A155593 [59660-30-9]

(4-Methyl-4H-[1,2,4]triazol-3-yl)methanol

Similarity: 0.68

Chemical Structure| 22882-41-3

A183454 [22882-41-3]

5-Isopropyl-4H-1,2,4-triazol-3-amine

Similarity: 0.60

Chemical Structure| 297172-18-0

A109629 [297172-18-0]

4-(4-Methyl-4H-1,2,4-triazol-3-yl)piperidine

Similarity: 0.59

Chemical Structure| 297171-80-3

A191784 [297171-80-3]

4-(4-Methyl-4H-1,2,4-triazol-3-yl)piperidine hydrochloride

Similarity: 0.58